GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.

GSK (GSK) plc announced that the U.S. Food and Drug Administration has approved a 200 mg/mL autoinjector of Benlysta, a B-lymphocyte ...

News zur GSK AKTIE und aktueller Realtime-Aktienkurs EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch ...